macbank's view, page-7

  1. 494 Posts.
    Hi asf,
    i've had a go with my model...
    Have attached two table - the first is the numbers without milestone payment - ie modeling royalty payments only:


    The second is with full milestone payments included:


    My numbers suggest strong upside value - assuming that: 1) Axiron can take further market share; and 2) that the overall US market grows; and 3) axiron can penetrate internal markets over time.

    Happy to provide further detail behind my assumptions - at a high level i forecast market share expansion and growth out to 2017 (peak market share) and then fade it at -2%pa until 2021 - where i calculate terminal value. Generics will become a factor in the market and i don't believe market share will be held in the face of that... so all conservative stuff.

    Happy to take any questions / criticisms... clearly the market does not see value here so what am i missing?

    Regards,
    mita
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.8¢
Change
0.000(0.00%)
Mkt cap ! $7.366M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
5 885323 1.7¢
 

Sellers (Offers)

Price($) Vol. No.
1.8¢ 503693 3
View Market Depth
Last trade - 10.23am 30/07/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.